(89 days)
No
The description focuses on the integration of existing software and a new digital detector, with no mention of AI or ML capabilities.
No
The device is described as a "Digital Radiography system" used for "digital image capture use in general radiographic examinations," which indicates it is an imaging device for diagnosis, not a therapeutic device.
Yes
The device is described as "Digital Radiography systems" which are used for "digital image capture use in general radiographic examinations." The output is evaluated by a "board certified radiologist," indicating that the images are intended for interpretation to establish a diagnosis.
No
The device description explicitly states it is an "integrated flat panel digital detector (FPD)" and integrates a "new digital x-ray receptor panel," indicating it includes hardware components beyond just software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states "digital image capture use in general radiographic examinations". This describes a medical imaging device used to capture images of the internal structures of the body, not a device used to examine specimens derived from the human body (like blood, urine, or tissue) in vitro (outside the body).
- Device Description: The description details a "Digital Radiography system" featuring an "integrated flat panel digital detector (FPD)". This is consistent with an X-ray imaging system.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples, reagents, or any processes typically associated with in vitro diagnostics.
Therefore, the Opal Chiro and 20/20 P-DR system is a medical imaging device, not an IVD.
N/A
Intended Use / Indications for Use
Opal Chiro and 20/20 P-DR are intended for digital image capture use in general radiographic examinations, wherever conventional screen-film systems may be used, excluding fluoroscopy, angiography and mammography.
Product codes
MQB
Device Description
The Opal Chiro and 20/20 P-DR system represents the straightforward integration of a new digital x-ray receptor panel (cleared in K062376) and our previously cleared (K123644 and K133139) software. The Opal Chiro and 20/20 P-DR are Digital Radiography systems, featuring an integrated flat panel digital detector (FPD). The Opal Chiro and 20/20 P-DR is designed to perform digital radiographic examinations as a replacement for conventional film. This integrated platform provides the benefits of PACS with the advantages of digital radiography for a filmless environment and improves cost effectiveness. The major functions and principle of operation of the Viztek PACS and the new receptor panel were not changed. Our main predicate is ViZion + DR, K123644, wherein we combined our OPAL-RAD software with two new digital panels. The upgrade kits are compatible with modern HF diagnostic X-ray generators like Sedecal and CPI. The 20/20 P-DR has been tested with X-Cel 700/900 series of generators.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Digital X-Ray
Anatomical Site
skull, chest, shoulders, spine, abdomen, pelvis, and extremities
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Clinical images were acquired and evaluated by a board certified radiologist who concluded the images from the new panel are as good as the images acquired with the predicate panel.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.1680 Stationary x-ray system.
(a)
Identification. A stationary x-ray system is a permanently installed diagnostic system intended to generate and control x-rays for examination of various anatomical regions. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). A radiographic contrast tray or radiology diagnostic kit intended for use with a stationary x-ray system only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of the department's name arranged in a circular fashion around a stylized symbol. The symbol features a series of three interconnected human profiles facing to the right, creating a sense of unity and collaboration.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
August 27, 2014
20/20 Imaging % Daniel Kamm, P.E. Principal Engineer 8870 Ravello Ct. Naples, Florida 34114
Re: K141435 Trade/Device Name: Opal Chiro, 20/20 P-DR Regulation Number: 21 CFR 892.1680 Regulation Name: Stationary X-ray System Regulatory Class: Class II Product Code: MQB Dated: May 28, 2014 Received: Mav 30, 2014
Dear Mr. Kamm:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
1
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Smh.7)
for
Janine M. Morris Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K141435
Device Name Opal Chiro and 20/20 P-DR
Indications for Use (Describe)
Opal Chiro and 20/20 P-DR are intended for digital image capture use in general radiographic examinations, wherever conventional screen-film systems may be used, excluding fluoroscopy, angiography and mammography.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
] Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
3
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
510(k) Summary 510(k) Number K141435 20/20 Imaging 2217 U.S. Highway 70 East Garner, NC 27529 Phone: 866.734.6234 Fax: 919.772.2810 Date Prepared: July 30, 2014 Contact: Bruce Ashby, Sales and Marketing Manager
-
- Identification of the Device:
Proprietary-Trade Name: Opal Chiro and 20/20 P-DR Flat Panel X-Ray Detector upgrade kits. Classification Name: Stationary X-ray System, Product Code MQB, Regulation 892.1680 Common/Usual Name: Digital X-Ray Receptor Panel
- Identification of the Device:
-
- Equivalent legally marketed devices: K123644, Vizion +DR, Viztek LLC.
-
- Indications for Use (intended use) Opal Chiro and 20/20 P-DR are intended for digital image capture use in general radiographic examinations, wherever conventional screen-film systems may be used, excluding fluoroscopy, angiography and mammography.
-
- Description of the Device: The Opal Chiro and 20/20 P-DR system represents the straightforward integration of a new digital x-ray receptor panel (cleared in K062376) and our previously cleared (K123644 and K133139) software. The Opal Chiro and 20/20 P-DR are Digital Radiography systems, featuring an integrated flat panel digital detector (FPD). The Opal Chiro and 20/20 P-DR is designed to perform digital radiographic examinations as a replacement for conventional film. This integrated platform provides the benefits of PACS with the advantages of digital radiography for a filmless environment and improves cost effectiveness. The major functions and principle of operation of the Viztek PACS and the new receptor panel were not changed. Our main predicate is ViZion + DR, K123644, wherein we combined our OPAL-RAD software with two new digital panels. The upgrade kits are compatible with modern HF diagnostic X-ray generators like Sedecal and CPI. The 20/20 P-DR has been tested with X-Cel 700/900 series of generators.
-
- Safety and Effectiveness, comparison to predicate device. The results of clinical image inspection, bench, and test laboratory results indicates that the new device is as safe and effective as the predicate devices. Clinical images collected demonstrate equal or better image quality as compared to our predicates.
| Characteristic | ViZion + DR, K123644 | Opal Chiro and 20/20 P-DR |
|---|---|---|
| Intended Use: | ViZion + DR is intended for digital image capture use in general radiographic examinations, wherever conventional screen-film systems may be used, excluding fluoroscopy, angiography and mammography. ViZion + allows imaging of the skull, chest, shoulders, spine, abdomen, pelvis, and extremities | Opal Chiro, model 20/20 C-DR and 20/20 P-DR are intended for digital image capture use in general radiographic examinations, wherever conventional screen-film systems may be used, excluding fluoroscopy, angiography and mammography. |
| Configuration | This submission is for the Digital Panel and Software only, no generator or stand provided. | This submission is for the Digital Panel and Software only, no generator or stand provided. |
6. Substantial Equivalence Chart
5
| Characteristic | ViZion + DR, K123644 | Opal Chiro and 20/20 P-DR |
|---|---|---|
| Digital Panel Sizes | iRay Technology (Shanghai) Ltd. For the | |
| 17" x 17" panel or 14" x 17" panel | The 17" x 17" panel stays the same. The | |
| 14" x 17" panel becomes a Naomi | ||
| model. A smaller size of 10" x 12" is | ||
| added for podiatry applications. | ||
| Digital panel | ||
| resolutions | 17" x 17" | |
| Pixel size 139 μm | ||
| $3064x3072$ pixels | ||
| 14" x 17" | ||
| Pixel size 150 μm | ||
| $2288×2800$ pixels | 14" x 17" | |
| Pixel pitch: Horiz. 7.2 μm x Vert. 5.6 μm | ||
| $7,872 x 6,144$ (48.36 megapixels) | ||
| 10" x 12" | ||
| Horiz. 7.2 μm x Vert. 5.6 μm | ||
| $4608 x 5904$ (27.2 megapixels) | ||
| Software | OpalRad Software, | |
| outputs a DICOM image. | SAME | |
| DICOM | Yes | Yes |
| Power source | AC Line | AC Line |
| Electrical safety and | ||
| EMC | Electrical Safety per IEC 60601-1 and | |
| EMC per IEC 60601-1-2. | Electrical Safety per IEC 60601-1 and | |
| EMC per IEC 60601-1-2. |
-
- Summary of Bench Testing Conducted: The included products have been separately cleared by FDA and are provided to the user unmodified. Verification of operation has been performed via clinical image acquisition and review. See the paragraph below.
-
- Summary of Clinical Testing: Clinical images were acquired and evaluated by a board certified radiologist who concluded the images from the new panel are as good as the images acquired with the predicate panel.
-
- Conclusion: After analyzing bench, clinical image, and external laboratory testing to applicable standards, it is the conclusion of 20/20 Imaging that the Opal Chiro and 20/20 P-DR are as safe and effective as the predicate device, have few technological differences, and has the same indications for use, thus rendering it substantially equivalent to the predicate device.